Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2024

Published by
Matej Mikulic,
Nov 28, 2024

This statistic depicts the market share of Neupogen (filgrastim) and its U.S. biosimilars from 2015 to 2024. In 2015, some 84 percent of filgrastim sales were attributable to Neupogen. However, as of Q4 2024, just 13 percent of filgrastim sales were attributable to Neupogen.

Filgrastim market share of Neupogen and its U.S. biosimilar competitors between 2015 and 2024

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2019

Region

United States

Survey time period

2015 to 2024

Supplementary notes

* Year to date November 2017. 
** MAT November 2018.

*** As of Q4 2024.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Generics and biosimilars "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Generics and biosimilars

Global overview

5

Top companies

5

U.S. market

6

Patent expiration

3

Savings

7

Biosimilars

7

Further related statistics

19

Further Content: You might find this interesting as well

Statistics

Topics

Generics and biosimilarsGlobal pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsDrug pricing in the U.S.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.